Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.

Pérez de Isla, Leopoldo

Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. [electronic resource] - Atherosclerosis 07 2019 - 40-45 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1879-1484

10.1016/j.atherosclerosis.2019.05.003 doi


Antibodies, Monoclonal--therapeutic use
Cholesterol, LDL--blood
Heterozygote
Humans
Hyperlipoproteinemia Type II--blood
Immunologic Factors--therapeutic use
Mathematical Concepts
Proprotein Convertase 9--immunology
Prospective Studies
Risk Assessment